**TABLE 2** Selected clinical information for patients found in the literature (cases 1-31) and on multi-institutional review (cases 32-41).

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Case | Age | Path. | 10 site(s) | Surgery | RT field: dose Gy (boost) | Chemotherapy | Response | Outcome | OS (months) | COD |
| 11 | 13y | NG | BG | Bx | WBI: 30 | Ifos, Carbo, Etop | CR | Alive | 21 | NA |
| 22 | 2y | T | CB | Bx | No | No | PD | Dead | 2 | Tumor |
| 33 | 7y | T | V | Bx | Yes: NR | No | PD | Dead | 2 | Tumor |
| 44 | 4m | T | BG | Bx | No | No | PD | Dead | 7 | Tumor |
| 55 | 9y | G | BG | STR | Yes: NR | No | CR | Alive | 36 | NA |
| 66 | 12y | NG | BG | STR | Yes: NR | Cisplatin, Etop | PR | Alive | NR | NA |
| 77 | 6y | NG | CB | STR | No | Cisplatin, Bleomycin, VBL, Cyclo | CR | Dead | NR | Sepsis |
| 88 | 12y | NG | BG | GTR | WBI: 21 | Cisplatin, Etop | PR | Dead | 21 | Pneumonia |
| 99 | 11y | NR | BG | None | Yes: NR | No | PD | Dead | NR | NR |
| 1010 | 10y | G | BG | STR | Focal: 30 | Cisplatin, Etop | CR | Alive | NR | NA |
| 1111 | 10y | G | BG/T | STR | No | No | PR | Dead | 1 | CP failure |
| 1211 | 20y | G | P | STR | Focal: 40 | Paraplatin, Etop | PR | Alive | NR | NA |
| 1312 | 9y | G | BG | STR | No | Cisplatin, Etop, Bleomycin | CR | Dead | 11 | Sepsis |
| 1412 | 3y | NG | CB | GTR | No | Cisplatin, Etop, Bleomycin | CR | Alive | 36 | NA |
| 1513 | 22y | NG | S | Bx | No | No | PR | Dead | 1.5 | Infection |
| 1614 | 35y | G | P/CB; Mets | Bx | Local: 42 | Carbo, Etop | CR | Dead | 35 | Tumor |
| 1715 | 17y | NG | BG | Bx | Yes: NR | Ifos, Cisplatin, Etop | PR | Alive | NR | NA |
| 1816 | 2m | T | CB | GTR | No | Cisplatin, Etop | CR | Alive | 46 | NA |
| 1917 | Newborn | T | P | GTR | No | No | CR | Alive | 3 | NA |
| 2018 | 12y | G | BG | STR | WBI: 40; Spine: 26 | No | CR | Alive | 60 | NA |
| 2119 | 14y | G | BG | Bx | WBI: 24 | Ifos, Cisplatin, Etop | CR | Alive | 16 | NA |
| 2220 | 1.5y | NG | PF | GTR | No | Cisplatin, Etop, Bleomycin | CR | Alive | 23 | NA |
| 2321 | 17y | NG | S | STR | No | Carbo, Etop, cisplatin, bentuximab-vendotin | CR | Alive | 24 | NA |
| 2422 | 18y | G | CB/P/MB; Mets | Bx | CSI: 23.4 | Carbo, Etop | PR | Alive | 21 | NA |
| 2523 | 15y | G | BG | Bx | WVI: 30 | Ifos, Cisplatin, Etop | PR | Dead | 11 | Sepsis |
| 2624 | 1y | NG | V | STR | Local: 41.4 | Ifos, Cisplatin, Etop | CR | Alive | 154 | NA |
| 2725 | 8y | NR | BG | Bx | WBI: 24; Local: 24 | Carboplatin, Etop, Ifos | PR | Alive | 60 | NA |
| 2826 | 6m | NG | P/S | None | CSI: 18 | Carboplatin, Etop, Ifos, Thiotepa | CR | Alive | 96 | NA |
| 2926 | 7m | G | S | STR | WVI: NR | No | CR | Dead | 48 | Moyamoya |
| 3026 | 4m | T | PF | GTR | No | Etop, Carboplatin, Bleomycin | CR | Alive | 216 | NA |
| 3126 | NR | G | S | None | WVI: NR | Etop, Carboplatin, Bleomycin | CR | Alive | 72 | NA |
| 32 | 15.8y | G | S; Mets | Bx | CSI: 24 (40) | No | PR | Alive | 6 | NA |
| 33 | 8.8y | NG | P | Bx | CSI: 36 | Carboplatin, Etop, Cyclo | CR | Alive | NR | NA |
| 34 | 2m | T | PF | GTR | No | No | CR | Alive | NR | NA |
| 35 | 17.2y | NG | S | STR | No | Carboplatin, Etop, Thiotepa | CR | Alive | NR | NA |
| 36 | 8y | G | S | Bx | WVI: 24 (36) | Carboplatin, Etop, Ifos | CR | Alive | 70 | NA |
| 37 | 12.7y | NG | S | None | WVI: NR | Carboplatin, Etop, Ifos, Cyclo, Thiotepa | CR | Alive | 14.5 | NA |
| 38 | 6.7y | NG | S/P/V | None | CSI: 18 (27) | Carbo, Etop, Ifos, Thiotepa | CR | Alive | 18 | NA |
| 39 | 4m | T | PF | GTR | No | Carboplatin, Etop, Bleomycin | CR | Alive | 255 | NA |
| 40 | 6.7y | G | S/P/V | None | CSI: 18 (27) | Carboplatin, Cyclo, Etop, VCR, Thiotepa | CR | Alive | 115 | NA |
| 41 | 34.7y | G | S | Bx | Local: 36 | No | PD | Alive | 10 | NA |

Abbreviations: 10, primary; BG, basal ganglia; Bx, biopsy; Carbo, carboplatin; CB, cerebellum; CSI, craniospinal irradiation; COD, cause of death; CP, cardiopulmonary; CR, complete response; Cyclo, cyclophosphamide; Etop, etoposide; GTR, gross total resection; Ifos, ifosfamide; mets, metastatic; m, months; NA, not applicable; NR, not reported; Path., pathology; PR, partial response; P, pineal; PF, posterior fossa; RT, radiotherapy; S, sellar/suprasellar; STR, subtotal resection; T, thalamus; Tx, treatment; VCR, vincristine; V, ventricle; WBI, whole brain irradiation; WVI, whole ventricular irradiation; y, years; #, number.

**Table 2 References**

1. Maeda Y, Yoshikawa K, Kajiwara K, et al. Intracranial yolk sac tumor in a patient with Down syndrome. *J Neurosurg Pediatr*. Jun 2011;7(6):604-8. doi:10.3171/2011.3.PEDS10500

2. Komiya K, Iwamoto H, Misugi K. A case of cerebellar tumor associated with Down's syndrome. *Congenital Anomalies*. 1975;15:212-213.

3. Nakato H, Kuwabara S, Maesako N, et al. [A case of Down's syndrome complicated by teratoma of the third ventricle of the brain (author's transl)]. *No To Shinkei*. Feb 1982;34(2):145-50.

4. Yamasaki S, Hamasaki Y. A infant case of brain tumor associated with Down's syndrome (in Japanese). Arch Jpn Chir1985. p. 305.

5. Fujita T, Yamada K, Saitoh H, Itoh S, Nakai O. Intracranial germinoma and Down's syndrome--case report. *Neurol Med Chir (Tokyo)*. Mar 1992;32(3):163-5. doi:10.2176/nmc.32.163

6. Oshita N, Yamashita K, Gotou K, Nagata I, Ueda H, Mitani T. [A case of endodermal sinus tumor in the basal ganglia associated with Down's syndrome]. *No Shinkei Geka*. Apr 1993;21(4):345-9.

7. Wada H, Kubo M, Wada T, et al. [A case report of a 6-year-old boy with intracranial yolk sac tumor treated by VAB-6 regimen]. *No Shinkei Geka*. Jan 1995;23(1):65-8.

8. Nakashima T, Nishimura Y, Sakai N, Yamada H, Hara A. Germinoma in cerebral hemisphere associated with Down syndrome. *Childs Nerv Syst*. Oct 1997;13(10):563-6. doi:10.1007/s003810050139

9. Hokezu Y, Okada A, Kanehisa Y, Nagamatsu K, Matsunaga M. Down syndrome associated with radiosensitive brain tumor. *Shenkei Naika*. 1987;26(8):3.

10. Tanabe M, Mizushima M, Anno Y, et al. Intracranial germinoma with Down's syndrome: a case report and review of the literature. *Surg Neurol*. Jan 1997;47(1):28-31. doi:10.1016/s0090-3019(96)00152-8

11. Matsumura N, Kurimoto M, Endo S, Fukuda O, Takaku A. Intracranial germinoma associated with Down's syndrome. Report of 2 cases. *Pediatr Neurosurg*. Oct 1998;29(4):199-202. doi:10.1159/000028721

12. Chik K, Li C, Shing MM, Leung T, Yuen PM. Intracranial germ cell tumors in children with and without Down syndrome. *J Pediatr Hematol Oncol*. 1999 Mar-Apr 1999;21(2):149-51. doi:10.1097/00043426-199903000-00012

13. Tan HW, Ty A, Goh SG, Wong MC, Hong A, Chuah KL. Pineal yolk sac tumour with a solid pattern: a case report in a Chinese adult man with Down's syndrome. *J Clin Pathol*. Aug 2004;57(8):882-4. doi:10.1136/jcp.2004.016659

14. Satoh S, Goto H, Izaki K, Sakuma H, Watanabe K. [Intracranial germinoma associated with Down syndrome: case report and review of literature]. *No Shinkei Geka*. Feb 2012;40(2):137-43.

15. Sugimoto K, Ideguchi M, Sadahiro H, et al. Yolk sac tumor of the bilateral basal ganglia in a patient with Down syndrome. *Brain Tumor Pathol*. Oct 2013;30(4):247-52. doi:10.1007/s10014-012-0134-9

16. Bakhtiar Y, Yonezawa H, Bohara M, et al. Posterior fossa immature teratoma in an infant with trisomy 21: A case report and review of the literature. *Surg Neurol Int*. 2012;3:100. doi:10.4103/2152-7806.100198

17. Robson CD, Price DL, Barnes PD, Taylor GA. Radiologic-pathologic conference of Children's Hospital Boston: pineal region mass in a neonate. *Pediatr Radiol*. Oct 1997;27(10):829-31. doi:10.1007/s002470050247

18. Hashimoto T, Sasagawa I, Ishigooka M, et al. Down's syndrome associated with intracranial germinoma and testicular embryonal carcinoma. *Urol Int*. 1995;55(2):120-2. doi:10.1159/000282766

19. Nodomi S, Umeda K, Ueno H, et al. Efficacy of Ifosfamide-Cisplatin-Etoposide (ICE) Chemotherapy for a CNS Germinoma in a Child With Down Syndrome. *J Pediatr Hematol Oncol*. 01 2017;39(1):e39-e42. doi:10.1097/MPH.0000000000000711

20. Endo S, Kobayashi H, Terasaka S, et al. Primary intracranial yolk sac tumor in the posterior fossa: case report of a child with Down syndrome. *Clin Neurol Neurosurg*. Jun 2013;115(6):811-3. doi:10.1016/j.clineuro.2012.07.023

21. Abu Arja MH, Conley SE, Salceda V, Al-Sufiani F, Boué DR, Finlay JL. Brentuximab-vedotin maintenance following chemotherapy without irradiation for primary intracranial embryonal carcinoma in down syndrome. *Childs Nerv Syst*. 04 2018;34(4):777-780. doi:10.1007/s00381-017-3690-9

22. Miyake Y, Adachi JI, Suzuki T, Mishima K, Sasaki A, Nishikawa R. Craniospinal Germinomas in Patient with Down Syndrome Successfully Treated with Standard-Dose Chemotherapy and Craniospinal Irradiation: Case Report and Literature Review. *World Neurosurg*. Dec 2017;108:995.e9-995.e15. doi:10.1016/j.wneu.2017.09.024

23. Tempaku A. Basal Ganglia Germinoma Associated with Down Syndrome in a Female Patient. *BAOJ Neurol*. 2018;4:50.

24. Takada A, Ii N, Hirayama M, et al. Long-term follow-up of intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial germ cell tumor. *J Neurosurg Pediatr*. 11 23 2018;23(3):317-324. doi:10.3171/2018.9.PEDS18181

25. Sadakata E, Yoshida K, Baba S, Fuku K, Matsuo T. A case of basal ganglia germ cell tumor associated with Down's syndrome. Nervous System in Children; 2021.

26. Dagri J, Torkildson J, Cheng J, et al. GC-08 CENTRAL NERVOUS SYSTEM (CNS) GERM CELL TUMORS (GCT) AND DOWN SYNDROME: TREATMENT STRATEGIES AND MORBIDITIES. Neuro Oncology (supplement)2012.